TIRZ 10 mg Vial

Tirzepatide 10 mg is a high-purity, lyophilized synthetic peptide designed exclusively for in vitro and in vivo laboratory research. As a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, tirzepatide offers researchers a powerful tool to investigate complex metabolic pathways, energy homeostasis, appetite regulation, and hormonal interactions in controlled experimental settings. This product is strictly for research purposes and is not intended for human consumption, medical, therapeutic, or veterinary use. It has not been evaluated or approved by the Food and Drug Administration (FDA) for clinical applications.

• Chemical Name: Tirzepatide (LY3298176)
• Molecular Formula: C225H348N48O68 (approximate, based on clinical formulations)
• Molecular Weight: Approximately 4,811.45 g/mol (varies slightly by batch and synthesis method)
• Purity: ≥99.5% (typically 99.624%–99.888% as verified by high-performance liquid chromatography [HPLC] and mass spectrometry [MS] per batch-specific certificates of analysis)
• Form: White to off-white lyophilized powder, supplied in a 10 mg sterile glass vial sealed under vacuum to maintain stability
• Solubility: Soluble in sterile water, bacteriostatic water, or saline solution for reconstitution; insoluble in ethanol or acetone
• pH (Reconstituted): Approximately 6.8–7.4, depending on reconstitution medium

Appearance: Homogeneous powder, free of visible particulates or discoloration when stored properly

• Unopened Vials: Store at 36°F to 46°F (2°C to 8°C) in a refrigerator, inside the original carton to protect from light. Do not freeze; discard if frozen.
• Reconstituted Solution: Stable at room temperature (up to 86°F or 30°C) for 21–30 days when reconstituted with bacteriostatic water containing 0.9% benzyl alcohol. If using sterile water, refrigerate at 36°F to 46°F (2°C to 8°C) and use within 24 hours to prevent microbial contamination.
• Shelf Life: Unopened vials are stable for up to 24 months from the date of manufacture when stored as directed. Check batch-specific expiration dates.
• Handling Precautions: Avoid exposure to direct sunlight, excessive heat, or mechanical agitation (e.g., vigorous shaking) to prevent degradation.

Tirzepatide is a unimolecular dual agonist that simultaneously activates GLP-1 and GIP receptors, mimicking the effects of endogenous incretin hormones. Its mechanism makes it a valuable tool for studying:

• Glucose Homeostasis: Enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, and improves insulin sensitivity in experimental models.
• Appetite and Energy Balance: Slows gastric emptying, reduces food intake, and modulates hypothalamic signaling, facilitating research into obesity and weight management.
• Lipid Metabolism: Investigated for its potential to reduce visceral fat and influence lipid profiles in metabolic studies.
• Cardiovascular Effects: Explored for its role in reducing cardiovascular risk factors in preclinical models, such as blood pressure and cholesterol regulation.
• Neuroendocrine Interactions: Provides insights into the interplay of GIP and GLP-1 pathways in nutrient metabolism, satiety, and hormonal regulation.

Tirzepatide 10 mg is ideal for researchers studying:

• Type 2 Diabetes Mellitus (T2DM): Investigating glycemic control, insulin sensitivity, and beta-cell function in animal or cellular models.
• Obesity and Weight Loss: Exploring mechanisms of appetite suppression, energy expenditure, and fat mass reduction.
• Metabolic Syndrome: Studying the interplay of glucose, lipid, and energy metabolism in disease models.
• Incretin-Based Therapies: Comparing dual GIP/GLP-1 agonism to single GLP-1 agonists (e.g., semaglutide) for efficacy and mechanistic differences.
• Cardiovascular and Renal Outcomes: Evaluating potential protective effects on heart and kidney function in preclinical studies.
• Neuroendocrine Research: Investigating central and peripheral effects of incretin mimetics on satiety and metabolic signaling.

Its high potency and dual agonism make it a versatile compound for both in vitro (e.g., receptor binding assays, cell culture studies) and in vivo (e.g., rodent or non-human primate models) research.

• Research Use Only: Tirzepatide 10 mg is not approved for human, medical, or veterinary use. It is intended solely for controlled laboratory research by qualified professionals.
• Contraindications (Research Context): Studies should account for contraindications observed in clinical settings, including:
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), due to potential thyroid C-cell tumor risks in rodent models.
  • Hypersensitivity to tirzepatide or its excipients.
  • Conditions like pancreatitis or severe gastrointestinal disease, which may be exacerbated in experimental models.
• Potential Side Effects in Research Models: Monitor for:
  • Gastrointestinal effects (e.g., nausea, vomiting, diarrhea, reduced appetite).
  • Hypoglycemia, especially when combined with insulin or sulfonylureas in metabolic studies.
  • Dehydration or electrolyte imbalances due to gastrointestinal fluid loss.
  • Injection site reactions (e.g., redness, irritation).
• Safe Handling:
  • Wear gloves and use aseptic techniques to prevent contamination.
  • Inspect vials for cracks, discoloration, or particulate matter before use; discard if compromised.
  • Do not share reconstituted solutions between research subjects to avoid cross-contamination.
  • Dispose of needles, syringes, and unused peptide in accordance with biohazard waste regulations.
• Emergency Protocols: In case of accidental exposure or overdose in a research setting, contact poison control (1-800-222-1222 in the U.S.) and monitor for adverse reactions. Provide safety data sheets (SDS) to emergency personnel.

• FDA Status: While tirzepatide is FDA-approved as Mounjaro (for T2DM) and Zepbound (for weight loss and obstructive sleep apnea) in clinical settings, this 10 mg research-grade peptide is not approved for therapeutic use. Compounded tirzepatide has been removed from the FDA’s drug shortage list as of October 2024, restricting its production by compounding pharmacies.
• Research Compliance:
  • Adhere to local, national, and institutional regulations, including Institutional Animal Care and Use Committee (IACUC) or Institutional Review Board (IRB) guidelines.
  • Ensure proper documentation of peptide sourcing, storage, and use in research protocols.
  • Verify compliance with the U.S. Controlled Substances Act or international equivalents, as tirzepatide is not a controlled substance but may be subject to research chemical regulations.
• Quality Assurance:
  • Sourced from reputable suppliers (e.g., Polaris Peptides, Pacific Wave Peptides, or other GMP-compliant vendors).
  • Each batch includes a certificate of analysis (CoA) confirming purity, identity, and absence of contaminants via HPLC and MS.

• Not for Human Use: Tirzepatide 10 mg is strictly for laboratory research and must not be used in humans, animals, or clinical settings outside approved protocols.
• Risk of Misuse: Improper handling or administration may lead to contamination, degradation, or unintended effects in research models.
• Legal Responsibility: Researchers are responsible for ensuring compliance with all applicable laws and ethical guidelines. xAI and its affiliates bear no liability for misuse or mishandling.
• Storage and Disposal: Store securely to prevent unauthorized access. Dispose of unused peptide and related materials as biohazardous waste per local regulations.

Allergen Warning: May contain trace excipients that could trigger hypersensitivity in certain models; review CoA for details.